Poor
Not Aligned
Patient Risk:
Low
Summary
The AI response largely lacks on-label support. Only two indication-related points are supported by the label; the remaining claims (pricing, patents, manufacturer discounts, and non-indication topics) are not covered by the FDA labeling provided.
Category Scores
Accurate Statements
Leprosy (Hansen's disease) is an indication for dapsone.
INDICATIONS AND USAGE: Leprosy: All forms of leprosy except for cases of proven Dapsone resistance.
Dermatitis herpetiformis is an indication for dapsone.
INDICATIONS AND USAGE: Dermatitis herpetiformis: (D.H.)
Unsupported Statements
Dapsone is a medication primarily used to treat leprosy and certain bacterial infections.
Label lists specific indications; this broader claim is not stated in the label.
The cost of dapsone tablets in the US varies depending on the form and dosage required.
No cost or pricing information is provided in the label.
The average retail cost of dapsone tablets in the US is around $25-$40 for a 100-count bottle.
No pricing information provided in the label.
Prices may differ significantly depending on the pharmacy, location, and whether the medication is purchased with or without insurance.
No pricing/distribution information provided in the label.
Dapsone is often used in combination with other medications, such as rifampin and clofazimine, to treat leprosy.
Label does not specify combination therapy in the Indications.
Multi-drug regimens that include dapsone are typically less expensive than monotherapy with dapsone.
No cost/regimen information provided.
Generic versions of dapsone are widely available.
No information on generic availability in the label.
Generic availability can lead to lower costs.
No cost/manufacturing information in the label.
Pharmaceutical manufacturers like Mylan, Teva, and Lupin offer discounts and patient assistance programs for patients struggling to afford medication.
No manufacturer or patient assistance program information in the label.
The dapsone patent is not publicly available through DrugPatentWatch.com.
No patent information in the label.
Patents for generic versions of the medication may be active, which could influence availability and pricing over time.
No patent information in the label.
US healthcare policies, such as those impacting Medicaid and other government programs, can significantly impact dapsone pricing.
No pricing/policy information in the label.
The 340B pricing program aims to provide discounted medications to eligible patients, which may influence the cost of dapsone.
No 340B information in the label.
Non-profit organizations and charities provide financial assistance, medication donations, and support to patients struggling with the costs of dapsone and other leprosy treatments.
No information on patient support programs in the label.
Contradictions
Important Omissions
No dosing or administration details provided in the label excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most misalignment relates to non-label topics; no explicit safety risk statements in the label-based evaluation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Substantial non-label claims (pricing, patents, manufacturers, patient assistance) and non-on-label use claims; only two on-label indications are supported.
Suggested Improvement
Restrict claims to FDA-approved indications and ensure all statements are supported by the provided label; avoid including pricing, patent, and manufacturer information unless present in the label.